Outlook Therapeutics Reports Third Quarter Fiscal Year 2026

Net Loss Q3 FY 2026

$20.3 million

Net loss attributable to common stockholders for the third quarter of fiscal year 2026.

Projected Annual Sales by 2030

$500 million

Potential annual sales of LYTENAVA in the U.S. by 2030.

Public Offering Proceeds

$51.1 million

Expected net proceeds from the public offering of common stock.

§ 01 Executive Snapshot

What: Outlook Therapeutics reported its third quarter fiscal results for 2026 and provided an update on its FDA-approved treatment LYTENAVA for wet AMD.
Who: Outlook Therapeutics, Bob Jahr (CEO), Albert Shirakian (CEO, Retina Vitreous Associates Medical Group), Miguel A. Busquets (Vice Chairman, EyeCare Partners).
Why it matters: LYTENAVA represents a significant advancement in the treatment of wet AMD, with potential annual sales exceeding $500 million by 2030, highlighting the company’s strategic positioning in a competitive market.

Outlook Therapeutics reported a net loss of $20.3 million for the third quarter, compared to a loss of $20.2 million in the same quarter last year.
The company expects LYTENAVA to exceed $500 million in annual U.S. sales by 2030, indicating strong market potential.
A public offering of 55,555,556 shares was announced, expected to yield approximately $51.1 million in net proceeds.

The approval of LYTENAVA marks a critical moment for Outlook Therapeutics, as it is the only FDA-approved ophthalmic formulation of bevacizumab, addressing a long-standing need in wet AMD treatment.
The company is preparing for a commercial launch strategy that considers the evolving market dynamics, including competition from biosimilars and affordability concerns.

The immediate consequence of LYTENAVA's approval is the potential to secure a significant share of the wet AMD market, enhancing Outlook Therapeutics' competitive positioning.
Long-term, the successful launch and adoption of LYTENAVA could establish Outlook Therapeutics as a key player in the ophthalmic treatment market, paving the way for future innovations and products.

Risks include potential regulatory challenges and the competitive landscape of anti-VEGF therapies, which may affect market penetration.
Infrastructure dependencies, such as the need for effective supply chain management and reimbursement strategies, could pose execution risks during the launch phase.

Outlook Therapeutics plans to submit an application for a permanent HCPCS code by October 1, 2026, which is crucial for reimbursement support following the launch.
Monitoring the market response to LYTENAVA and the uptake among retina practices will be critical indicators of the product's success post-launch.

§ 07

What is LYTENAVA?

LYTENAVA is an FDA-approved treatment for wet AMD, representing a significant advancement in the field.

Why is LYTENAVA important for Outlook Therapeutics?

LYTENAVA's approval positions Outlook Therapeutics strategically in the market, with potential annual sales exceeding $500 million by 2030.

How much net loss did Outlook Therapeutics report for the third quarter?

Outlook Therapeutics reported a net loss of $20.3 million for the third quarter.

When does Outlook Therapeutics plan to submit an application for a permanent HCPCS code?

The company plans to submit the application by October 1, 2026.